Ocular Therapeutix Adds Oculis CEO Riad Sherif — Seung Suh Hong To Leave Board
Sherif’s director awards include options on 88,000 shares and restricted stock units covering 28,000 shares.
Ocular Therapeutix, which develops treatments for eye diseases, elected Riad Sherif to its board Friday, while Seung Suh Hong notified the company that he would leave at year-end. Sherif, chief executive of Oculis Holding AG, joined immediately, according to an SEC filing made public Monday.
Share Awards Vest Over Three Years
Sherif received 88,000 stock options and restricted stock units covering 28,000 shares under Ocular’s pay policy for directors who are not employees. Both awards vest annually over three years.
The options let Sherif purchase shares at $6.60 each, matching OCUL’s $6.60 closing price Friday on the Nasdaq Global Market. His initial board term runs through the 2027 annual shareholder meeting.
Hong’s departure takes effect December 31, 2026. The company said his decision was unrelated to a disagreement with management or fellow directors about its business, policies or practices.
From Alcon To Oculis
Sherif, 58, has been Oculis’s chief executive and a director since December 2017. His eye-care experience includes running Alcon’s Europe, Middle East and Africa region from March 2014 to May 2016, when the business was part of Novartis.
His next role was entrepreneur in residence at the Novartis Venture Fund, from June 2016 to September 2017. Earlier Novartis positions included leading its Canadian pharmaceuticals business and global transplant and immunology sales, alongside regional leadership jobs in Latin America. He also co-founded vaccine manufacturing joint venture Sinergium Biotech.
Before Novartis, Sherif worked in marketing and general management at Sanofi from 1993 to 2000, including leading its Algerian business. He has held a board seat at Revenio Group Oyj since March 2022.
Ocular’s Eye-Treatment Pipeline
Ocular’s drug-delivery technology, ELUTYX, uses a dissolving hydrogel to release medicine inside the eye over time. Its commercial product, DEXTENZA, is an FDA-approved corticosteroid insert used for inflammation and pain following eye surgery and itching associated with allergic conjunctivitis.
The company’s annual report for 2025 says DEXTENZA has been used in nearly 750,000 eyes since launch. Its lead investigational treatment, AXPAXLI, is an axitinib implant in late-stage trials for wet age-related macular degeneration and diabetic retinal disease.
A glaucoma treatment candidate, OTX-TIC, has completed a mid-stage trial. AffaMed Therapeutics holds rights to that candidate and DEXTENZA in certain Asian markets.
Sources
- 8-K Filing — OCULAR THERAPEUTIX, INC (OCUL) — SEC EDGAR